Companies/Nkarta, Inc.

Company profile

Nkarta, Inc.

NASDAQ: NKTX · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001787400Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

47D

FH 52DQ 37GM —SS 54

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, market scale · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$104.1M

Employees

108

as of 2026-08-13

Market cap

$171.0M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$104.1M-$104.1M2025

Operating income-$122.0M-$122.0M2025

Total assets$404.2M$404.2M2025

Liabilities$91.9M$91.9M2025

Equity$312.3M$312.3M2025

Revenue trend

FY2020 – FY2025 · USD

$115.0k

FY20

FY21

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Nkarta, Inc.’s revenue?

Nkarta, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Eupraxia Pharmaceuticals Inc.42D Corbus Pharmaceuticals Holdings, Inc.45D Immuneering Corporation43D OnKure Therapeutics, Inc.46D TuHURA Biosciences, Inc.36D Spruce Biosciences, Inc.40D

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEOPaul J. Hastings

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: NKTX

Employees108

IPO date2020-07-10

Latest filings

10-Q2026-08-10 8-K2026-08-10 8-K2026-06-11 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-23 8-K2026-03-26 8-K2026-03-25

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.